Helus Pharma Inc(HELP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:28 PM ET (Korea 10/30 05:28)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.25 | Insider Own | 28.57% | Shs Outstand | 62.0M | Perf Week | 2% |
| Market Cap | 0.78B | Forward P/E | - | EPS next Y | 20.76% | Insider Trans | 3.92% | Shs Float | 52.2M | Perf Month | -12.86% |
| Enterprise Value | 0.62B | PEG | - | EPS next Q | -0.7 | Inst Own | 36.18% | Short Float | 5.77% | Perf Quarter | 36.96% |
| Income | -0.17B | P/S | - | EPS this Y | 37.2% | Inst Trans | 11.46% | Short Ratio | 1.77 | Perf Half Y | 101.69% |
| Sales | 0.00B | P/B | 2.74 | EPS next 5Y | 27.67% | ROA | -72.78% | Short Interest | 3.01M | Perf YTD | 30.93% |
| Book/sh | 3.91 | P/C | 4.7 | EPS past 3/5Y | 16.7% 14.41% | ROE | -86.94% | 52W High | -29.31% ($15.15) | Perf Year | 43.18% |
| Cash/sh | 2.28 | P/FCF | - | Sales past 3/5Y | - | ROIC | -70.72% | 52W Low | 184.84% ($3.76) | Perf 3Y | -54.47% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 7.55% | Gross Margin | - | Volatility(W/M) | 8.74% 8.29% | Perf 5Y | -84.93% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.88 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.97 | EPS Q/Q | 16.81% | Profit Margin | - | RSI (14) | 45.75 | Recom | 1.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.97 | Sales Q/Q | - | SMA20 | -0.84% ($10.8) | Beta | 0.63 | Target Price | $43.75 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/14 | SMA50 | -10.75% ($12) | Rel Volume | 0.46 | Prev Close | $10.91 |
| Employees | 100 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -7% - | SMA200 | 39.05% ($7.7) | Avg Volume(3M) | 1.70M | Price | $10.71 |
| IPO | 2019/9/13 | Option/Short | Yes/Yes | Trades | 5126 | Volume | 785,333 | Change | -1.83% |
🧠 Help Therapeutics (HELP) is a clinical-stage pharmaceutical company developing central nervous system therapeutics aimed at depression and anxiety disorders. Its core focus is a family of synthetic serotonin agonists that activate the serotonin pathway to promote neuroplasticity, advancing a pipeline of novel drugs in the mental health space.
Over the past 1 year, roughly in the middle
29% below its 1-year high.
Traded less than usual. That is 46% of its average volume.
HELP has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +37.2% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -84.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 36.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
PSIL AdvisorShares Psychedelics ETF 0.04% It ranks #178 of 594 in the industry
Based on market cap of $782M.
AVBP#177 ArriVent BioPharma Inc $786M PER - HELP#178 Helus Pharma Inc $782M PER - 
ARDX#179 Ardelyx Inc $772M PER - 
OABI#180 OmniAb Inc $760M PER - 
ANNX#181 Annexon Inc $760M PER - 
FAQ
What kind of company is HELP?
HELP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of HELP?
The market cap of HELP is approximately $782M, ranking 2,787 within its sector.
What is the 52-week high and low for HELP?
HELP has recorded a 52-week high of $15.15 and a low of $3.76.
